Bringing Results in von Willebrand Disease

Humate-P® the most prescribed and most tested VWF/FVIII replacement treatment, with a long history of success1,2

With 36-month room temperature storage


The most prescribed VWF/FVIII replacement therapy1
Learn More >>


Effective hemostatic control for all VWD types and across multiple types of bleeds
Learn More >>


Integrated Safety System helps meet high product quality and safety standards
Learn More >>

Young adults sitting on a bench homepage Mom and child walking together homepage Father and son playing soccer homepage Father and son flying a kite homepage

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Humate-P® is approved to treat and prevent bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P also treats spontaneous or trauma-induced bleeding episodes in adults and children with von Willebrand disease (VWD) and prevents excessive bleeding during and after surgery in patients with mild, moderate or severe VWD. Humate-P is not known to prevent spontaneous bleeding episodes.

Do not take Humate-P if you have had extreme sensitivity or an allergic response to antihemophilic or von Willebrand factor preparations. Your doctor will monitor you for events related to abnormal blood clotting.

Humate-P is made from human blood and could contain infectious agents. The risk that these agents may transmit disease cannot be completely eliminated, but has been reduced by screening plasma donors and testing donated plasma for certain viruses, and by inactivating and/or removing viruses during manufacturing.

In studies, more than 5% of patients reported the following adverse reactions to Humate-P: allergic/anaphylactic reactions, including hives, chest tightness, rash, itching, and swelling. The most common adverse reactions after surgery were bleeding at the wound or infusion site, and nosebleeds.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

© CSL Behring 2019. The product information on this site is intended for US residents only. HUM / 10-11-0010(1) 8/2015


  1. Data on File. Available from CSL Behring as DOF HUM-001.
  2. Berntorp E, Archey W, Auerswald G, et al. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/Humate-P: history and clinical performance. Eur J Haematol. 2008;80(Suppl 70):3-35.